Mount Sinai Researchers Launch Global Strategy to Combat Liver Cancer Using Framework of Disease Hallmarks

New research in Cell defines the hallmarks of liver cancer. Discover how Mount Sinai is using genetic mutations to guide precision medicine and immunotherapy.

By: AXL Media

Published: Apr 17, 2026, 11:26 AM EDT

Source: Information for this report was sourced from The Mount Sinai Hospital / Mount Sinai School of Medicine

A Modern Scientific Framework for a Global Health Crisis

Primary liver cancer has emerged as the third leading cause of cancer related mortality worldwide, claiming approximately 830,000 lives each year. In a major effort to reverse this trend, researchers from Mount Sinai and Hospital Clínic de Barcelona have published a comprehensive analysis in the journal Cell. By applying the influential Hallmarks of Cancer framework to liver tumors, the study bridges the gap between complex biological processes and clinical application. This roadmap arrives as the global medical community marks the 25th anniversary of the hallmark model, providing clinicians with a structured method to categorize and attack the specific vulnerabilities of individual tumors.

Biological Divergence Between Major Liver Cancer Strains

The research highlights critical distinctions between the two primary forms of the disease, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. While hepatocellular carcinoma is characterized by unregulated growth signaling and a sophisticated ability to evade the human immune system, bile duct cancers often exhibit significantly altered metabolism. According to Dr. Josep M. Llovet, understanding these distinct biological drivers is essential for moving away from empirical treatments toward a more strategic approach. This refined classification allows medical teams to identify why certain tumors resist standard therapies while others remain highly susceptible to intervention.

Precision Oncology and the Rise of Targetable Mutations

One of the most significant findings of the review is the identification of actionable genetic alterations in roughly 45 percent of intrahepatic cholangiocarcinoma cases. These tumors frequently harbor specific mutations, such as FGFR2 fusions and IDH1 or BRAF alterations, which can be neutralized by existing or emerging targeted drugs. This high percentage of targetable traits represents a shift in how biliary tract cancers are managed, placing a greater emphasis on molecular profiling. By matching the genetic signature of a tumor to a specific inhibitor, physicians can now offer more effective treatments that minimize the systemic toxicity associated with traditional chemotherapy.